The Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel) and LYFGENIA™ (lovotibeglogene autotemcel), the first two gene therapies for the treatment of sickle cell disease  in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). 

In 2016, our 8-year-old son Justin was airlifted to CHOP for emergency brain surgery. It hit us out of nowhere. When his sister and brother visited, Child Life came in with things like Legos and Play-Doh to distract them from his scary head wrap and get them to just play together. It took the fear out of the room.

Protecting teens’ brains while they play competitive sports.

The innovative Food as Medicine program bring food and nutrition education to families facing food instability.

CHOP’s Culinary Medicine program develops recipes that can help ease physical symptoms or otherwise improve children’s health.

A Q&A with Tami Benton, MD, who has led the Department of Child and Adolescent Psychiatry and Behavioral Sciences since 2010.

As a research trainee in infectious diseases, Dr. Molnar studies metabolic regulators to develop promising antimalarial therapies. Follow a day in her life.

Children’s Hospital of Philadelphia (CHOP) has received a $6.4 million gift from the family of Connor Boyle, a Central Bucks East High School graduate who died at age 18 from osteosarcoma. This three-year gift, named The Connor Initiative: Precision Therapeutics for Osteosarcoma & Rare Cancers, will support cutting-edge research in osteosarcoma and other rare cancers.

CHOP’s HI Center, a Frontier Program, continues to set the standard for caring for children with congenital hyperinsulinism.

On Sunday, October 8, Children’s Hospital of Philadelphia (CHOP) hosted its annual Buddy Walk & Family Fun Day benefiting the hospital’s Trisomy 21 (Down syndrome) Program, which supports healthier futures for patients and helps to improve the lives of individuals with Down syndrome.